Application of pharmacodynamic principles: From theory to practice

Antibiotic Optimization: Concepts and Strategies in Clinical Practice

Volumn , Issue , 2004, Pages 353-381

  Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746371778     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (69)

1. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review Scand J Infect Dis; 1991; 74(suppl):63–70.
2. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration J Infect Dis; 1987; 155: 93–99.
3. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia Am J Med; 1984; 77:657–762.
4. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram negative bacteremia J Infect Dis; 1984; 149:443–448.
5. Gilbert DN. Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides Clin Infect Dis; 1997; 24:816–819.
6. Rodvold KA. Pharmacodynamics of anti-infective therapy: taking what we know to the patient’s bedside Pharmacotherapy; 2001; 21(11 pt 2):319S-330S.
7. Daenen S, de Vries-Hospers H. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime Lancet; 1988; 1:937.
8. Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin- resistant, ampicillin-resistant Enterococcus faecium Microb Drug Resist; 1995; 1:249–253.
9. Tam VH, McKinnon PS, Levine DP, Brandel SM, Rybak MJ. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review Pharmacotherapy.; 2000; 20:1116–1119.
10. Domenig C, Traunmuller F, Kozek S, Wisser W, Klepetko W, Steininger R, Spiss C, Thalhammer F. Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multi-drug resistant Pseudomonas aeruginosa infection Transplantation; 2001; 71:744–745.
11. Raehl CL, Bond CA. 1998 National Clinical Pharmacy Services Study Pharmacotherapy; 2000; 20:436–460.
12. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis; 1998; 26:1–12.
13. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae Diagn Microb Infect Dis; 2000; 38:151–157.
14. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. Population pharmacokinetics and use ofMonte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis Antimicrob Agents Chemother; 2001; 45: 3468–3473.
15. Grant EM, Kuti JL, Nicolau DP, Nightingale CH, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous infusion piperacillin-tazobactam program in a large community teaching hospital Pharmacotherapy; 2002; 22:471–483.
16. Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale CH, Murakawa T, Ambrose PG, Eds Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel Dekker Inc, 2002:1–22.
17. Maller R, Ahrne H, Eilard T, Eriksson I, Lausen I. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses J Antimicrob Chemother; 1991; 27:121S–128S.
18. Prins JM, Buller HR, Kuijper EJ, Tange Ra, Speelman P. Once versus thrice daily gentamicin in patients with serious infections Lancet; 1993; 341:335–339.
19. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia Ann Intern Med; 1993; 119:584–593.
20. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once versus twice-daily amikacin dosing in critically ill adult and pediatric patients J Antimicrob Chemother; 1991; 28:753–764.
21. Gilbert DN, Lee BL, Dworkin RJ, Leggett JL, Chambers HF, Modin G, Tauber MG, Sande MA. A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate Am J Med; 1998; 105:182–191.
22. Mingeot-Leclerq M, Tulkens PM. Aminoglycosides: nephrotoxicity Antimicrob Agents Chemother; 1999; 43:1003–1012.
23. Tulkens P. Experimental studies on nephrotoxoicty of aminoglycosides at low doses Am J Med; 1986; 80:105–114.
24. Giuliano RA, Verpooten GA, Verbist L, Wedeen RP, De Broe ME. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats J Pharmacol Exp Ther; 1986; 236:470–475.
25. Galoe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety Eur J Clin Pharmacol; 1995; 48:39–43.
26. Freeman CD, Strayer AH. Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials Pharmacotherapy; 1996; 16: 1093–1102.
27. Hatala R, Dinh T, Cook D. Once-daily aminoglycoside dosing in immunocompromised adults: a meta-analysis Ann Intern Med; 1996; 124:717–725.
28. Munckhof WJ, Grayson JL, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given with once daily or as divided doses J Antimicrob Chemother; 1996; 37:645–663.
29. Chuck SK, Raber SR, Rodvold KA, Areff D. National survey of extended-interval aminoglycoside dosing Clin Infect Dis; 2000; 30:433–439.
30. Kashuba ADM, Bertino JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram- negative organisms Antimicrob Agents Chemother; 1998; 42: 1842–1844.
31. Wallace AW, Jones M, Bertino JS. Evaluation of four once-daily aminoglycoside dosing nomograms Pharmacotherapy; 2002; 22: 1077–1083.
32. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients Antimicrob Agents Chemother; 1995; 39:650–655.
33. Infrequent Aminoglycoside Dosing, from Barnes-Jewish Hospital at Washington University Medical Center. Available from http://internalmed.wustl.edu/divisions/house_staff/aminoglyco sides.html (accessed September 2002).
34. Anaizi N. Once daily dosing of aminoglycosides: a consensus document Int J Clin Pharmacol Ther; 1997; 35:223–226.
35. Gilbert DN, Moellering RC, Sande MA, Eds The Sanford Guide to Antimicrobial Therapy 2001. 31st ed. Hyde Park. VT: Antimicrobial Therapy, Inc., 2001.
36. Hitt CM, Klepser ME, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacoeconomic impact of once-daily aminoglycoside administration Pharmacotherapy; 1997; 17:810–814.
37. Freeman CD, Nightingale CH, Nicolau DP, Belliveau PP, Quintiliani R. Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens Am J Hosp Pharm; 1994; 51:1782–1787.
38. Freeman CD, Nightingale CH, Nicolau DP, Belliveau PP, Tessier PR, Fu Q, Xuan DW, Quintiliani R. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam Pharmacotherapy; 1994; 14: 185–190.
39. Sullivan MC, Nightingale CH, Quintiliani R, Sweeney KR. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam Pharmacotherapy; 1995; 15:479–486.
40. Quintiliani R, Hitt CM, Ambrose PG, Nicolau DP, Nightingale CH. Ceftizoxime/metronidazole replace cefotetan for intraabdominal infections Formulary; 1997; 32:740–745.
41. Barbut F, Decre D, Burghoffer B, Lesage D, Delisle F, Lalande V, Delmee M, Avesani V, Sano N, Coudert C, Petit JC. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997 Antimicrob Agent Chemother; 1999; 43:2607–2611.
42. Zosyn Package Insert. Lederle Piperacillin, Inc., Carolina, Puerto Rico, 2002.
43. Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens Antimicrob Agent Chemother; 1997; 41:2511–2517.
44. Kim MK, Capitano B, Mattoes HM, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Pharmacokinetic and pharmaco-dynamic evaluation of two dosing regimens for piperacillin tazobactam Pharmacotherapy; 2002; 22:569–577.
45. Klepser ME, Marangos MN, Zhu Z, Nicolau DP, Quintiliani R, Nightingale CH. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa Antimicrob Agent Chemother; 1997; 41:435–439.
46. Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375g q4h and 4.5 g q6h. 75g q4h and 4.5 g q6h Chemotherapy; 2002; 48:59–63.
47. Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam J Antimicrob Chemo ther; 2001; 48:259–267.
48. Hitt CM, Patel KB, Nicolau DP, Zhu Z, Nightingale CH. Influence of piperacillin-tazobactam on pharmacokinetics of gentamicin given once daily Am J Health Syst Pharm; 1997; 54: 2704–2708.
49. Richerson MA, Ambrose PG, Bui KQ, Grant E, Nicolau DP, Nightingale CH, Quintiliani R. Pharmacokinetic and economic evaluation of piperacillin/tazobactam administered as either continuous or intermittent infusion with once-daily gentamicin Infect Dis Clin Pract; 1999; 8:195–200.
50. Burgess DS, Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing Clin Ther; 2002; 24: 1090–1104.
51. Jones RN, Croco MA, Kugler KC, Pfaller MA, Beach ML. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) Diagn Microbiol Infect Dis; 2000; 37:115–125.
52. Kuti JL, Grant EM, Sutherland CA, Ye M, Zhou W, McCarter Y, Nightingale CH, Nicolau DP. Divergence in MIC distributions of Pseudomonas aeruginosa for piperacillin and piperacillin/tazobactam. C distributions of Pseudomonas aeruginosa for piperacillin and piperacillin/tazobactam J Infect Dis Pharmacother; 2001; 5:41–51.
53. Facca BF, Triesenberg SN, Barr LL. Population pharmacokinetics of continuous infusion piperacillin-tazobactam J Infect Dis Pharmacother; 2002; 5:51–67.
54. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis Diagn Microbiol Infect Dis; 2002; 44:51–57.
55. Lomaestro BM, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic evaluation of extending the infusion time of piperacillin/tazobactam doses using Monte Carlo analysis [abstr]. In: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington. DC: American Society for Microbiology, 2001:36.
56. Maxipime package insert. Dura Pharmaceuticals, Inc., San Diego, CA, 2002.
57. Paterson DL, Clarke L, Ndirangu MW, Kuznetsov D. Use of pharmacodynamic principles and stochastic modeling to choose an optional empiric cefepime dose for suspected Pseudomonas aeruginosa infections within a single institution [abstract]. In: Programs and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington. DC: American Society for Microbiology, 2002:9.
58. Merrem package insert. AstraZeneca Pharmaceuticals, LP, Wilmington, DE, 2001.
59. Kuti JL, Maglio D, Nightingale CH, Nicolau DP. Economic benefit of a meropenem dosing strategy based on pharmacodynamic concepts Am J Health Syst Pharm; 2002; 60:565–568.
60. Patel RP, Cook SE. Stability of meropenem in intravenous solutions Am J Health Syst Pharm; 1997; 54:412–421.
61. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5g and 2g every 8h administered as a 3h infusion [abstr]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington. DC: American Society for Microbiology, 2002:18.
62. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Pharmacodynamic comparison of prolonged and traditional infusions of meropenem in gram negative bacteria [abstr]. In: Programs and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington. DC: American Society for Microbiology, 2002:8.
63. Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hol-lenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H. Continuous infusion versus intermittent administration of meropenem in critically ill patients J Antimicrob Chemother; 1999; 43:523–527.
64. Kuti JL, Nightingale CH, Knauft R, Nicolau DP. Pharmacokinetics of continuously infused meropenem in adults with cystic fibrosis [abstr] Am J Resp Crit Care Med; 2003; 167:A372.
65. Grant EM, Zhong MK, Ambrose PG, Nicolau DP, Nightingale CH, Quintiliani R. Stability of meropenem in a portable infusion device in a cold pouch Am J Health Syst Pharm; 2000; 57: 992–995.
66. Klepser ME, Banevicius MA, Quintiliaqni R, Nightingale CH. Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods Antimicrob Agent Chemother; 1996; 40:1941–1944.
67. Klepser ME, Nicolau DP, Quintiliani R, Nightingale CH. Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis Antimicrob Agents Che Mother; 1997; 41:630–635.
68. Lewis RE, Klepser ME, Ernst EJ, Lund BC, Biedenbach DJ, Jones RN. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection Antimicrob Agents Chemother; 1999; 43:2005–2009.
69. Nicolau DP, Belliveau PP, Nightingale CH, Quintiliani R, Freeman CD. Implementation of a once-daily aminoglycoside program in a large community-teaching hospital Hosp Pharm; 1995; 30:674–680.